Skip contents

NewsRSS

For news items, click on the titles / links below.

  • Xendo's Integrated Drug Development concept accelerates biopharmaceutical development projects
  • Immulite 2000 Analyzer
  • Immunogenicity analysis and multiplex biomarker assays with new ECL equipment at Xendo
  • Full clinical research services now offered
  • Xendo's Bioanalysis and Drug Metabolism introduces new LIMS
  • Disposables Reach Out to New Markets
  • TI Pharma project on metabolic stability of NCE's takes off
  • Xendo joins the Ride for the Roses
  • Xendo CTM's director interviewed by C2W
  • New Managing Director in Denmark
  • The bisphosphonates bioanalytical challenge – Xendo’s answer: the risedronate case
  • Focus Scandinavian activities
  • Xendo CTM, a new life science company in The Netherlands
  • Business Management services expanded
  • Clinical pharmacology of chiral compounds – an expertise of Xendo
  • GMP status van Nederlandse ziekenhuizen
  • Xendo Newsletter special edition on bioanalysis and biomarkers - out now!
  • Xendo conducts human microdosing (human phase 0) study for Biofrontera AG
  • On-line clinical studies – LPS challenge testing
  • On-line clinical studies – full integration of CPrU and bioanalysis
  • Biotech News interview with Koos Koops and Ard Tijsterman
  • Xendo partner in Top Institute Pharma

Go to:
Begin of the page
Contents
End of the page

You are now here

  • Home
  • News

Xendo B.V.

One company. One philosophy. One vision

Navigation

  • Company
  • Quality
  • News
  • Services
  • Careers
  • Contact

Global links

  • Sitemap
  • Search

Xendo is open to pharma